Anna Georgieva Kondic is a mathematician by training, receiving her PhD in Mathematical Physics from Duke University in 1998. Anna holds a degree in Business Administration from NYU, with a specialization in negotiations. Anna has long experience and understanding in modelling and quantitative decision support in both in R&D and HEOR spaces. She is responsible for the early HEOR and analytics services before ph3 stage, and bridge/synergize business and services across iDD and AL. She will also help developing our Decision Analytics business in North America.
Most recently, Anna was a distinguished scientist in the Data and Economic Sciences department at Merck and Co, where she is responsible for the implementation of economic models in the early space of R&D. Prior to her current position, Anna was part of Merck’s quantitative pharmacology department, where she led the filing strategy and clinical pharmacology dossier for Merck’s immunomodulatory drug Keytruda, currently approved for multiple tumor types. Before Merck, Anna spent 11 years at Novartis, where she supported arthritis, osteoporosis, oncology, diabetes and cardio-vascular disease using both empirical and mechanistic models to aid quantitative decision making.